Tirzepatide targets two pathways
Human studies have also provided evidence for cardioprotective functions of GLP-1 analogs and DPP-4 inhibitors in both diabetics and non-diabetics, although larger, randomized trials are still required
Recent studies emphasize early intervention, an initial bolus for optimal GR saturation, and continuous infusion to sustain therapeutic levels
Huge thanks to my co authors Nick Lemke, Jonathan Stieber, Moritz Fuchs, Zhilong Weng, Marie-Lisa Eich, Thomas Lingscheidt, Fabian Dominik Mairinger, Reinhard Bttner, Yuri Tolkach and Anirban Mukhopadhyay
Controlled appetite and cravings Increase resting energy expenditure Improved sleep Lower Risk of Hypoglycemia- tirzepatide has a lower risk of causing hypoglycemia (dangerously low blood sugar), a common side effect of many diabetes treatments
Most formulas aim to support your gut microbiome, the community of bacteria that helps with digestion, stool consistency, inflammation balance, and metabolism